Correction: Cheng et al. NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan. Biomedicines 2022, 10, 2362

We would like to identify and amend errors in a previously published paper [1]. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Error in Figure

In the original publication, a component of Figure 2 (Figure 2d) was missing. The data values in the figure are published and cited in the original manuscript text (first paragraph from ‘secondary outcomes’ section). The corrected Figure 2 appears below.

Additionally, incorrect values were included in Figure 3c (the week 52 data value of 6 MWT). Correct values are reported in the original manuscript text (Table 6 and second paragraph from ‘secondary outcomes’ section). The corrected Figure 3 appears below.

Error in Table

In the original publication, there was a mistake in Tables 3–5 as published, in that 95% CI was incorrectly written as 95% C.I. There was an extra row in Table 3. The corrected

Table 3. Logistic regression analysis for death between weeks 0–104.

	n/N (%)	Odds Ratio (95% CI)	p-Value
All treated patients	28/88 (31.8)
Age (year)
<75	13/49 (26.5)
≥75	15/39 (38.5)	1.891 (0.532, 6.726)	0.325
Gender
Women	2/17 (11.8)
Men	26/71 (36.6)	9.230 (0.826, 103.114)	0.071
Smoking
Never	14/41 (34.1)
Current or ex-smoker	14/47 (29.8)	1.049 (0.225, 4.889)	0.951
BMI
<27	23/61 (37.7)
≥27	5/27 (18.5)	0.364 (0.075, 1.767)	0.21
GAP stage at baseline
Stage I	2/14 (14.3)
Stage II	9/29 (31.0)	0.936 (0.115, 7.600)	0.951
Stage III	17/44 (38.6)	0.548 (0.061, 4.932)	0.592
FVC (% pred.) at baseline
≥65%	13/52 (25.0)
<65%	15/35 (42.9)	3.980 (0.994, 15.937)	0.051
Emphysema at baseline
No	24/73 (32.9)
Yes	4/15 (26.7)	0.411 (0.085, 1.986)	0.269
Obstructive sleep apnea risk
Low risk	4/15 (26.7)
Intermediate risk	17/54 (31.5)	0.281 (0.031, 2.571)	0.261
High risk	7/19 (36.8)	0.312 (0.021, 4.643)	0.398
Any comorbidity
None	3/10 (30.0)
Any	25/78 (32.1)	0.140 (0.012, 1.684)	0.121
Cardiovascular-related comorbidity
None	13/37 (35.1)
Any	15/51 (29.4)	0.823 (0.191, 3.551)	0.794
Respirator-related comorbidity
None	9/36 (25.0)
Any	19/52 (36.5)	16.286 (1.996, 132.880)	0.009
Bronchodilator use
No	10/39 (25.6)
Yes	18/49 (36.7)	2.163 (0.564, 8.303)	0.261
Decline in FVC (% pred.)
No	15/56 (26.8)
Yes	8/23 (34.8)	1.116 (0.245, 5.083)	0.888

BMI, body mass index; CI, confidence interval; FVC, forced vital capacity; GAP, Gender, Age, Physiology; pred, predicted. A p-value < 0.05 is significant. Sleep apnea was evaluated according to the STOP-Bang scoring model. Variability in gender, smoke, GAP stage, risk associated with obstructive sleep apnea, or comorbidities were removed from the model where quasi-complete separation of data points were detected.

,

Table 4. Logistic regression analysis for acute exacerbation/death in treated patients between weeks 0–104.

	n/N (%)	Odds Ratio (95% CI)	p-Value
All treated patients	40/88 (45.5)
Age (year)
<75	18/49 (36.7)
≥75	22/39 (56.4)	1.882 (0.604, 5.866)	0.275
Gender
Women	4/17 (23.5)
Men	36/71 (50.7)	6.877 (0.880, 53.745)	0.066
Smoking
Never	21/41 (51.2)
Current or ex-smoker	19/47 (40.4)	0.530 (0.134, 2.087)	0.364
BMI
<27	33/61 (54.1)
≥27	7/27 (25.9)	0.393 (0.105, 1.468)	0.165
GAP stage at baseline
Stage I	4/14 (28.6)
Stage II	11/29 (37.9)	0.713 (0.125, 4.063)	0.703
Stage III	25/44 (56.8)	0.831 (0.135, 5.109)	0.842
FVC (% pred.) at baseline
≥65%	20/52 (38.5)
<65%	20/35 (57.1)	2.544 (0.740, 8.752)	0.139
Emphysema at baseline
No	34/73 (46.6)
Yes	6/15 (40.0)	0.470 (0.110, 2.002)	0.307
Obstructive sleep apnea risk
Low risk	5/15 (33.3)
Intermediate risk	26/54 (48.1)	0.362 (0.048, 2.697)	0.321
High risk	9/19 (47.4)	0.278 (0.023, 3.341)	0.313
Any comorbidity
None	3/10 (30.0)
Any	37/78 (47.4)	0.737 (0.094, 5.800)	0.772
Cardiovascular-related comorbidity
None	15/37 (40.5)
Any	25/51 (49.0)	1.577 (0.426, 5.838)	0.495
Respirator-related comorbidity
None	14/36 (38.9)
Any	26/52 (50.0)	4.848 (1.147, 20.489)	0.032 *
Bronchodilator use
No	18/39 (46.2)
Yes	22/49 (44.9)	0.896 (0.290, 2.763)	0.848
Decline in FVC (% pred.)
No	22/56 (39.3)
Yes	13/23 (56.5)	1.203 (0.330, 4.383)	0.779

BMI, body mass index; CI, confidence interval; FVC, forced vital capacity; GAP, Gender, Age, Physiology; pred, predicted. A * p-value < 0.05 is significant. Sleep apnea was evaluated according to the STOP-Bang scoring model. Variability in gender, smoke, GAP stage, risk associated with obstructive sleep apnea, or comorbidities were removed from the model where quasi-complete separation of data points were detected.

and

Table 5. Logistic regression analysis for acute exacerbation between weeks 53–104.

	n/N (%)	Odds Ratio (95% CI)	p-Value
All treated patients	5/88 (5.7)
Age (year)
<75	4/49 (8.2)
≥75	1/39 (2.6)	0.235 (0.014, 3.826)	0.309
BMI
<27	2/61 (3.3)
≥27	3/27 (11.1)	3.978 (0.379, 41.798)	0.25
FVC (% pred.) at baseline
≥65%	3/52 (5.8)
<65%	2/35 (5.7)	2.276 (0.242, 21.443)	0.472
Emphysema at baseline
No	4/73 (5.5)
Yes	1/15 (6.7)	1.095 (0.059, 20.410)	0.951
Cardiovascular-related comorbidity
None	1/37 (2.7)
Any	4/51 (7.8)	6.488 (0.497, 84.764)	0.154
Respirator-related comorbidity
None	2/36 (5.6)
Any	3/52 (5.8)	0.097 (0.004, 2.415)	0.155
Bronchodilator use
No	1/39 (2.6)
Yes	4/49 (8.2)	8.860 (0.429, 183.081)	0.158
Decline in FVC (% pred.)
No	2/56 (3.6)
Yes	3/23 (13.0)	10.887 (1.033, 114.784)	0.047

BMI, body mass index; FVC, forced vital capacity, GAP, Gender-Age-Physiology, pred, predicted. p-value < 0.05 is significant.

appear below.

Text Correction

In the Results Section, Section 3.2.1., Figure 2a was mis-cited in the second sentence of paragraphs 1 and 2 and they should be Figure S1. The corrected sentences appear below.

The mean ± SD of absolute annual change from baseline in FVC was −114.3 ± 441.5 mL at week 52 and −142.5 ± 610.8 mL at week 100 (Figure S1).

There was no significant change from baseline (mean ± SD) for absolute DL_CO, which ranged from −2.6 to 0.1 mL/min/mmHg (Figure S1) during the 2-year follow-up.

In the Discussion section, there was an error in the original publication. The “mean ± 1.7%” is updated to “±1.7%” in the first paragraph of the discussion for consistency with the results. The corrected sentence appears below.

Despite significantly compromised baseline functionality, antifibrotic therapy with nintedanib or pirfenidone limited further deteriorations of respiratory functions, especially with respect to annual changes from baseline in percent predicted FVC (±1.7%), without adversely affecting the quality of life.

Modifications in Author Contributions

The corrected Author Contributions appears below.

Conceptualization, S.-L.C., H.-C.W. and D.-W.P.; validation, H.-C.W. and D.-W.P.; investigation, S.-L.C., C.-C.S., C.-F.C., J.-Y.H., K.-C.K., L.-W.H., C.-H.L., W.-F.F., H.-C.W. and D.-W.P.; data curation, S.-L.C., C.-C.S., C.-F.C., J.-Y.H., K.-C.K., L.-W.H., C.-H.L., W.-F.F., H.-C.W. and D.-W.P.; writing—review and editing, S.-L.C.; visualization, S.-L.C., H.-C.W. and D.-W.P. All authors have read and agreed to the published version of the manuscript.